| Literature DB >> 30467492 |
Francesca Maradonna1,2, Oliana Carnevali1,2.
Abstract
Exposure to potential Endocrine Disrupting Chemicals (EDCs) pose a documented risk to both wildlife and human health. Many studies so far described declining sperm counts, genital malformations, early puberty onset, highlighting the negative impact on reproduction caused by the exposure to many anthropogenic chemicals. In the last years, increasing evidence suggested that these compounds, other than altering reproduction, affect metabolism and induce the onset of obesity and metabolic disorders. According to the "environmental obesogens" hypothesis, evidence exists that exposure to potential EDCs during critical periods when adipocytes are differentiating, and organs are developing, can induce diseases that manifest later in the life. This review summarizes the effects occurring at the hepatic level in different animal models, describing morphological alterations and changes of molecular pathways elicited by the toxicant exposure. Results currently available demonstrated that these chemicals impair normal metabolic processes via interaction with members of the nuclear receptor superfamily, including steroid hormone receptors, thyroid hormone receptors, retinoid X receptors, peroxisome proliferator-activated receptors, liver X receptors, and farnesoid X receptors. In addition, novel results revealed that EDC exposure can either affect circadian rhythms as well as up-regulate the expression of signals belonging to the endocannabinoid system, in both cases leading to a remarkable increase of lipid accumulation. These results warrant further research and increase the interest toward the identification of new mechanisms for EDC metabolic alterations. The last part of this review article condenses recent evidences on the ability of potential EDCs to cause "transgenerational effects" by a single prenatal or early life exposure. On this regard, there is compelling evidence that epigenetic modifications link developmental environmental insults to adult disease susceptibility. This review will contribute to summarize the mechanisms underlying the insurgence of EDC-induced metabolic alterations as well as to build integrated strategies for their better management. In fact, despite the large number of results obtained so far, there is still a great demand for the development of frameworks that can integrate mechanistic and toxicological/epidemiological observations. This would increase legal and governmental institution awareness on this critical environmental issue responsible for negative consequences in both wild species and human health.Entities:
Keywords: epigenetic; metabolic disorders; phthalates; reproduction; zebrafish (Danio rerio)
Year: 2018 PMID: 30467492 PMCID: PMC6236061 DOI: 10.3389/fendo.2018.00654
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1PPAR signaling pathway. PPARs are nuclear hormone receptors that are activated by fatty acids and their derivatives. PPAR α, δ/β, ɤ, show different expression patterns in vertebrates. Each of them is encoded by a separate gene and binds fatty acids, eicosanoids and synthetic ligands. Key genes are reported. PPARα/RXR heterodimer activates the transcription of genes involved in lipid metabolism, including transport, lipogenesis, cholesterol metabolism and adipocyte differentiation. PPARβ/RXR heterodimers activate the transcription of signal involved in fatty acid transport, fatty acid oxidation, and signal triggering final adipocyte differentiation. PPARɤ/RXR heterodimers are involved in different steps of lipid metabolism and regulate the transcription of signal responsible for adipocyte differentiation and gluconeogenesis. ACBP, Acyl-CoA-binding protein; ACS, Acetyl-coenzyme A synthetase; ACO, andacyl-CoA oxidase; ACOX1, Peroxisomal acyl-coenzyme A oxidase 1; ADIPOQ, adiponectin; aP2, adipocyte fatty acid binding protein 2; Apo-AI, apolipoprotein A1; ApoAII, apolipoprotein AII; Apo-AV, apolipoprotein AV; FABP1, fatty acid binding protein 1; FABP3, fatty acid binding protein 1; FATP1/4, Fatty acid transport protein 1–4; GyK, glycerol kinase; LPL, lipoprotein lipase; LXRα, Liver receptor α; Pepck, phosphoenolpyruvate carboxykinase; SCD-1 stearoyl-CoA desaturase-1.
Figure 2Activation of lipogenic and adipogenic pathways. PPARs (α, β/δ, and γ) belong to the nuclear hormone receptor superfamily and are ligand-activated transcription factors activated by fatty acids, fatty acid derivatives (e.g., eicosanoids), endocannabinoids and potential EDCs. PPAR and RXR dimers form important transcription activators which upon binding PPAR response elements can modulate many important cell functions, e.g., PPARα-RXR dimers activate genes controlling peroxisome proliferation, fatty acid metabolism and lipid homeostasis; PPARγ-RXR dimers affect adipocyte differentiation. C/EBPs are a family of nuclear activators, transiently expressed very early during adipocyte differentiation. C/EBPβ/δ activate the expression of of C/EBPa. Furthermore, the expression of C/EBPa and PPARγ is sustained by apositive feedback loop. Both proteins cooperatively promote downstream adipocyte-related genes transcription. SREBPs are activators of the complete program of hepatic cholesterol and fatty acid synthesis. SREBP-1 preferentially activates genes of fatty acid and triglyceride metabolism, whereas SREBP-2 preferentially activates genes of cholesterol metabolism. SCAP transports SREBPs from the ER to the Golgi apparatus, where is cleaved by two proteases, Site-1 protease (S1P) and Site-2 protease (S2P). nuclear SREBP (nSREBP), translocates to the nucleus, where it activates transcription of multiple target genes. SREBP-2 responsive genes include those for the enzymes HMG-CoA synthase, HMG-CoA reductase, farnesyl diphosphate synthase, and squalene synthase. SREBP-1 responsive genes include those for ATP citrate lyase and acetyl-CoA carboxylase and fatty acid synthase, the fatty acid elongase complex, (27) stearoyl-CoA desaturase, and glycerol-3-phosphate acyltransferase (28) Finally both SREBP forms activate three genes required to generate NADPH, which is consumed at multiple stages in these lipid biosynthetic pathways (29).
Figure 3Modulation of lipid content and metabolism in Seabream fed xenobiotics. (A) False color images of liver sections from C, NP, t-OP, BPA, and xenobiotic mixtures representing the topographical distribution of lipids. Adapted from Carnevali et al. (72). (B) mRNA variations in the different experimental groups. “+” upregulation, “–” downregulation, “/” no changes respect to control values. Experimental groups C, control fish receiving the commercial feed; NP, fed the commercial feed enriched with 5 mg/kg bw NP; t-OP, fed the commercial feed enriched with 5 mg/kg bw t-OP; BPA, fed the commercial feed enriched with 5 mg/kg bw BPA; NP + t-OP, fed the commercial feed enriched with 5 mg/kg bw NP + 5 mg/kg bw t-OP; BPA + t-OP, fed the commercial feed enriched with 5 mg/kg bw BPA + 5 mg/kg bw t-OP; BPA + NP, fed the commercial feed enriched with 5 mg/kg bw BPA + 5 mg/kg bw NP; NBO, fed the commercial feed enriched with 5 mg/kg bw NP + 5 mg/kg bw BPA + 5 mg/kg bw t-OP. Seabream picture by Dr. Marco Graziano http://tiktaalikillustrations.com.
Main biological effects reported in different cell and animal models exposed to potential EDCs.
| Benzophenone 3 (BP-3) | Zebrafish, | Obesity induction and alteration of circadian rhythms | ( |
| Bisphenol A (BPA) | 3T3-L1 pre-adipocytes | Adipocyte metabolic dysfunction and inflammation | ( |
| Zebrafish | Induction of TAG accumulation by up-regulation of ECS | ( | |
| HHL-5 cells | Induction of TAG accumulation by up-regulation of ECS | ( | |
| Zebrafish | Increased presence of hepatic lipid vacuoles, caused by alteration of the ECS | ( | |
| Increased TAG storage and FA synthesis, | ( | ||
| Evidence of the miRNome involvement in lipid synthesis, oxidation and related diseases | ( | ||
| Seabream, | Hepatic lipid accumulation associated to a decrease of lipid mobilization | ( | |
| Alteration of hepatic structure lipids and TAG content and decreased phospholipids and glycogen abundance | ( | ||
| Marine medaka, | Upregulation of | ( | |
| Brominated diphenyl ether 47 (BDE-47) | 3T3-L1 pre-adipocytes | Increased levels of | ( |
| Cypermethrin (CYP), atrazine (ATZ), 17α-ethynyestradiol (EE2) | C57BL/6J mice | Alteration of the hepatic levels of PPARα, PPARɤ, and SREBP1C | ( |
| Dibutyltin (DBT) | Human MSCs | C/EBPα, PPARγ2, FABP4, FSP27, LPL upregulation | ( |
| Dichlorodiphenyltrichloroethane (DDT) | Hsd:Sprague Dawley®™SD®™ Harlan | Obesity induction in males. | ( |
| Di(2-ethylhexyl) phthalate (DEHP) | HepG2 cells | Activation of the SREBP-1c and PPARα-signaling pathway | ( |
| Zebrafish | Alteration of FOXA2 and FOXA3 transcription factor networks', “Metabolic pathways,” “metabolism of amino acids and derivatives,” “metabolism of lipids and lipoproteins,” and “fatty acid, triacylglycerol, and ketone body metabolism” | ( | |
| Up-regulation of hepatic PPARα, Cb1, and SREBP levels, | ( | ||
| Sprague-Dawley rats | Hepatic steatosis, associated to inflammation, lipid peroxidation, oedema of the liver cells and hepatic damage | ( | |
| Di-isodecyl- phthalate (DiDP) | Seabream | PPAR-mediated regulation of | ( |
| DiNP | Zebrafish | Upregulation of orexigenic and hepatosteatosis signals, deregulation of the peripheral and central ECS and lipid metabolism | ( |
| DiNP | Seabream | Alteration of hepatic structure lipids and triglycerides content and decreased phospholipids and glycogen abundance | ( |
| Diethylene glycol dibenzoate (DGB) | Zebrafish | Increase of de novo lipogenesis, cholesterol esters, TAG production and potential conversion of lipids into apolipoprotein particles | ( |
| Seabream | PPARα agonist, stimulation of key lipolytic genes and downregulation of ECS | ( | |
| Methoxychlor | Sprague-Dawley rats | Obesity induction in females. | ( |
| BPA, DEHP and dibutylphthalate (DBP) mixture | Sprague-Dawley rats | Obesity induction. Transgenerational study | ( |
| Nonylphenol (NP) | Sprague-Dawley rats | Hepatic | ( |
| Wistar rats | Obesity induction, increased levels of cholesterol and leptin and alteration of the expression of genes involved in lipogenesis and adipogenesis. | ( | |
| Seabream | Hepatosteatosis, alteration of lipid metabolism | ( | |
| BPA, NP, | Seabream | Alteration of lipid metabolism | ( |
| Polycyclic aromatic hydrocarbon (PAH) mixture | BALB/cByj mice | Increased | ( |
| RXR-specific ligands LG100268 and AGN195203 | African clawed frog, | Ectopic adipocyte formation around the gonads | ( |
| Tributyltin (TBT) | murine 3T3-L1 adipocytes | RXR-PPARɤ-mediated pro-adipogenesis in liver and adipose tissue | ( |
| Increase the number of differentiated adipocites. | ( | ||
| C57BL/6 mice | Lipid accumulation in adipose tissues and onset of hepatic steatosis | ( | |
| Increased lipid accumulation in differentiated adipocytes associated to an increase of early adipogenesis markers, Pparɤ and Fapb4. | ( | ||
| African clawed frog | Activation of RXR/PPARɤ pathways | ( | |
| Zebrafish | Male: increased body weight, hepatosomatic index, hepatic TAG abundance and expression of adipogenesis and lipogenesis genes | ( | |
| Obesity induction and alteration of circadian rhythms | ( | ||
| Trout ( | Promotion of adipocytes differentiation by enhancing PPARγ and C/EBPα protein expression | ( | |
| 2,3,7,8-Tetrachlorodibenzodioxin (TCDD) | C57BL/6J mice | Sex specific modulation of mRNA levels involved in adipose tissue and hepatic metabolism, inflammation, xenobiotic metabolism and endocrine disruption | ( |
| AHR mediates obesity and fatty liver onset | ( | ||
| Tetrabrominated bisphenol A (TBBPA) | Zebrafish | Obesity induction and alteration of circadian rhythms | ( |
| Seabream | Hepatosteatosis, alteration of lipid metabolism | ( | |
| Triclosan (TCS) | Zebrafish | Upstream regulation of miR-125b | ( |
| Human MSCs | decreasing | ( | |
| Zebrafish | impaired mRNA expression levels of β-oxidation transcripts and lipid β-oxidation genes, including | ( | |
| Tyhriphenyltin (TPT) | Trout Primary adipocite culture | Promotion of adipocytes differentiation by enhancing PPARγ and C/EBPα protein expression | ( |
| tris (1,3-dichloroisopropyl) phosphate (TDCIPP) | Zebrafish | Obesity induction and alteration of circadian rhythms | ( |